Best response during maintenance therapy according to cytogenetic abnormalities
| . | Standard risk, %, n = 111 . | High risk, %, n = 28 . | P . | ||
|---|---|---|---|---|---|
| VT . | VP . | VT . | VP . | ||
| IF− CR | 48 | 41 | 47 | 39 | NS |
| IF+ CR | 10 | 11 | 7 | 8 | NS |
| PR | 37 | 45 | 40 | 54 | NS |
| MR | 3 | 2 | 7 | NS | |
| . | Standard risk, %, n = 111 . | High risk, %, n = 28 . | P . | ||
|---|---|---|---|---|---|
| VT . | VP . | VT . | VP . | ||
| IF− CR | 48 | 41 | 47 | 39 | NS |
| IF+ CR | 10 | 11 | 7 | 8 | NS |
| PR | 37 | 45 | 40 | 54 | NS |
| MR | 3 | 2 | 7 | NS | |
Data are percentages.
VT indicates bortezomib plus thalidomide; VP, bortezomib plus prednisone; IF− CR, immunofixation-negative complete remission; IF+ CR, immunofixation-positive complete remission; PR, partial response; MR, minor response; and NS, not significant.